Section Navigation
Section Navigation
- Module 4 Overview
Co-Occurring Conditions - 0%Lesson 1
Latent Tuberculosis InfectionActivities- 0%Lesson 2
Opportunistic Infections: PreventionActivities- 0%Lesson 3
Opportunistic Infections: TreatmentActivities- 0%Lesson 4
Sexually Transmitted InfectionsActivities- 0%Lesson 5
Hepatitis B CoinfectionActivities- 0%Lesson 6
Hepatitis C CoinfectionActivitiesLesson 1. Latent Tuberculosis Infection
Learning Objective Performance Indicators
- Discuss the epidemiology of tuberculosis and HIV coinfection in the United States
- State the rationale for screening for latent TB in people with HIV
- Describe and compare recommended screening tests for latent TB in people with HIV
- List recommended options for the treatment of latent TB in people with HIV
- Summarize common drug interactions between medications used to treat latent TB and common antiretroviral medications
About this Lesson
Learning Objective Performance Indicators
- Discuss the epidemiology of tuberculosis and HIV coinfection in the United States
- State the rationale for screening for latent TB in people with HIV
- Describe and compare recommended screening tests for latent TB in people with HIV
- List recommended options for the treatment of latent TB in people with HIV
- Summarize common drug interactions between medications used to treat latent TB and common antiretroviral medications
Activities in this Lesson
Share by e-mail
Check
-On-
Learning
QuestionsThe Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.You must be signed in to customize your interaction with these questions.
- 0%Lesson 2
Funded by
Health Resources and Services Administration (HRSA)
Created at
University of Washington
An AETC Program
Part of
IDEA Platform
CME provided byUniversity of Alabama Birmingham
CNE approved byOregon Nurses Association
Copyright © 2025 National HIV Curriculum
The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.
Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant